We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+433.28%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
989

Sector Composition

Rank Sector Weight
1 Technology 6.08%
2 Financials 6.03%
3 Industrials 5.01%
4 Consumer Discretionary 4.73%
5 Healthcare 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OGEN icon
7726
Oragenics
OGEN
$2.26M
$10K ﹤0.01%
+2
New +$12.6K
RPRX
7727
DELISTED
Repros Therapeutics Inc.
RPRX
$10K ﹤0.01%
+15,518
New +$7.83K
EPIX
7728
DELISTED
ESSA Pharma
EPIX
$9K ﹤0.01%
2,079
-1,092
-34% -$5.68K
GAU
7729
Galiano Gold
GAU
$455M
$9K ﹤0.01%
12,760
-8,970
-41% -$7.27K
LGC.WS
7730
DELISTED
Legacy Acquisition Corp. Warrants, exercisable for one-half of one share of Class A Common Stock for
LGC.WS
$9K ﹤0.01%
+22,000
New +$10.6K
IPCI
7731
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$9K ﹤0.01%
1,126
-959
-46% -$8.71K
JRJR
7732
DELISTED
JRjr33, Inc.
JRJR
$9K ﹤0.01%
+51,128
New +$11K
RPRX
7733
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$9K ﹤0.01%
13,300
-7,500
-36% -$3.79K
XTNT icon
7734
Xtant Medical Holdings
XTNT
$60.3M
$8K ﹤0.01%
+1,138
New +$8.97K
GLOWE
7735
DELISTED
GLOWPOINT INC
GLOWE
$8K ﹤0.01%
23,539
-131,208
-85% -$44.6K
CPHI icon
7736
China Pharma Holdings
CPHI
$45M
$7K ﹤0.01%
75
-237
-76% -$20.6K
SLS icon
7737
PUT
SELLAS Life Sciences
SLS
$1.97B
$7K ﹤0.01%
18
+6
+50% +$2.9K
WYY icon
7738
WidePoint Corp
WYY
$101M
$7K ﹤0.01%
+1,131
New +$6.95K
GEVO icon
7739
CALL
Gevo
GEVO
$360M
$6K ﹤0.01%
+500
New +$6.38K
PSTV icon
7740
Plus Therapeutics
PSTV
$26.6M
0
RLOG
7741
DELISTED
Rand Logistics, Inc.
RLOG
$4K ﹤0.01%
25,101
-75,690
-75% -$28.3K
SLS icon
7742
CALL
SELLAS Life Sciences
SLS
$1.97B
$3K ﹤0.01%
+8
New +$3.87K
AAT
7743
American Assets Trust
AAT
$1.45B
-61,954
Closed -$2.46M
AB icon
7744
PUT
AllianceBernstein
AB
$3.43B
-8,500
Closed -$207K
ABEV icon
7745
PUT
Ambev
ABEV
$48.1B
-11,300
Closed -$74K
ACHV icon
7746
Achieve Life Sciences
ACHV
$659M
-55
Closed -$22K
ADAP
7747
DELISTED
Adaptimmune Therapeutics
ADAP
-83,423
Closed -$683K
AEMD icon
7748
Aethlon Medical
AEMD
$1.75M
-1
Closed -$19K
AGNC icon
7749
AGNC Investment
AGNC
$12.4B
-3,459,699
Closed -$71.1M
AGZ icon
7750
iShares Agency Bond ETF
AGZ
$558M
-8,472
Closed -$963K

Similar funds

Citadel Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Citadel Advisors held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Citadel Advisors deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.1% of assets, down from 7% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Citadel Advisors's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Citadel Advisors added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Citadel Advisors's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Citadel Advisors fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Citadel Advisors's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Citadel Advisors opened 1,440 new positions and closed 989 in Q4 2017.
  • Citadel Advisors's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.